News | October 30, 2023
Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
The companies plan to start a pivotal Phase 3 trial in the coming months
RHTC will address a long-standing healthcare access issue for all the local population
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Subscribe To Our Newsletter & Stay Updated
